[{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"258815b3-da9e-48e7-8a38-615cfaef4dbd","acronym":"TROPION-Lung02","url":"https://clinicaltrials.gov/study/NCT04526691","created_at":"2021-01-18T21:40:42.295Z","updated_at":"2025-02-25T14:07:50.610Z","phase":"Phase 1","brief_title":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","source_id_and_acronym":"NCT04526691 - TROPION-Lung02","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2","pipe":" | ","alterations":" KRAS mutation","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2026","study_completion_date":" 04/15/2026","last_update_posted":"2025-02-19"},{"id":"cb3cb1db-2e3e-4730-8a0c-9a0d27e26ede","acronym":"","url":"https://clinicaltrials.gov/study/NCT06471673","created_at":"2025-02-26T10:47:22.224Z","updated_at":"2025-02-26T10:47:22.224Z","phase":"Phase 1/2","brief_title":"A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer","source_id_and_acronym":"NCT06471673","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" PD-L1 • PD-L2 • PRAME","pipe":"","alterations":" ","tags":["PD-L1 • PD-L2 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • cyclophosphamide • Bria-OTS"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/29/2024","start_date":" 05/29/2024","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-08-26"},{"id":"8a480ed5-36f4-4c94-a8ca-7de2924f7398","acronym":"","url":"https://clinicaltrials.gov/study/NCT03211416","created_at":"2021-01-18T15:50:22.610Z","updated_at":"2025-02-25T16:06:31.337Z","phase":"Phase 1/2","brief_title":"Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer","source_id_and_acronym":"NCT03211416","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • PD-L2","pipe":"","alterations":" ","tags":["PD-L1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • sorafenib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 03/07/2023","primary_completion_date":" 03/07/2023","study_txt":" Completion: 12/07/2024","study_completion_date":" 12/07/2024","last_update_posted":"2024-07-03"},{"id":"897d9629-7c12-4d49-92b0-10b4a3de5a1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02973997","created_at":"2025-02-26T08:59:58.704Z","updated_at":"2025-02-26T08:59:58.704Z","phase":"Phase 2","brief_title":"Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)","source_id_and_acronym":"NCT02973997","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" CD8 • PD-L2","pipe":"","alterations":" ","tags":["CD8 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 10/08/2023","study_completion_date":" 10/08/2023","last_update_posted":"2024-07-01"},{"id":"b947b4bf-3a48-42a6-9074-c4d0df75bda7","acronym":"NU 15U06","url":"https://clinicaltrials.gov/study/NCT02808143","created_at":"2025-02-25T16:04:51.366Z","updated_at":"2025-02-25T16:04:51.366Z","phase":"Phase 1","brief_title":"Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT02808143 - NU 15U06","lead_sponsor":"Northwestern University","biomarkers":" PD-L1 • PD-1 • PD-L2","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 02/10/2017","start_date":" 02/10/2017","primary_txt":" Primary completion: 05/15/2020","primary_completion_date":" 05/15/2020","study_txt":" Completion: 08/05/2022","study_completion_date":" 08/05/2022","last_update_posted":"2024-06-26"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"6d0b40ae-0057-41ed-9ea5-d6965f8e7aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238027","created_at":"2021-01-18T16:00:03.519Z","updated_at":"2024-07-02T16:35:03.052Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03238027","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Niktimvo (axatilimab-csfr)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2024-05-17"},{"id":"18ee0f81-3adf-4bd7-8334-4d0c4101af0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886036","created_at":"2023-11-15T20:15:29.821Z","updated_at":"2024-07-02T16:35:07.221Z","phase":"Phase 2","brief_title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma","source_id_and_acronym":"NCT05886036","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • PD-1 • PD-L2","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • PD-1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-04-29"},{"id":"9684c401-b6e9-4a7c-98a3-a622c0960a7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05518032","created_at":"2022-08-26T11:59:04.967Z","updated_at":"2024-07-02T16:35:09.884Z","phase":"Phase 2","brief_title":"Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)","source_id_and_acronym":"NCT05518032","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • PD-L2","pipe":" | ","alterations":" RAS wild-type","tags":["PD-L1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-04-12"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"fb41c942-0118-47f1-8463-173313f6902a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02830594","created_at":"2021-01-18T13:52:49.963Z","updated_at":"2024-07-02T16:35:18.878Z","phase":"Phase 2","brief_title":"Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT02830594","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • PD-L2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/05/2016","start_date":" 10/05/2016","primary_txt":" Primary completion: 01/20/2022","primary_completion_date":" 01/20/2022","study_txt":" Completion: 01/16/2024","study_completion_date":" 01/16/2024","last_update_posted":"2024-02-19"},{"id":"acb2717e-a36e-41ca-907e-430b8037d287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03012230","created_at":"2021-01-18T14:49:16.634Z","updated_at":"2024-07-02T16:35:21.613Z","phase":"Phase 1","brief_title":"Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer","source_id_and_acronym":"NCT03012230","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2","pipe":" | ","alterations":" PD-L1 expression • PD-L1 amplification • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 amplification • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/06/2017","start_date":" 12/06/2017","primary_txt":" Primary completion: 01/06/2023","primary_completion_date":" 01/06/2023","study_txt":" Completion: 03/08/2023","study_completion_date":" 03/08/2023","last_update_posted":"2024-01-31"},{"id":"bfe72445-b65e-479e-a443-59c9975a1b02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03969446","created_at":"2024-01-03T17:17:46.574Z","updated_at":"2024-07-02T16:35:24.733Z","phase":"Phase 1","brief_title":"Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory","source_id_and_acronym":"NCT03969446","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • PD-1 • PD-L2","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Venclexta (venetoclax) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/04/2020","start_date":" 05/04/2020","primary_txt":" Primary completion: 11/04/2025","primary_completion_date":" 11/04/2025","study_txt":" Completion: 11/04/2025","study_completion_date":" 11/04/2025","last_update_posted":"2024-01-03"},{"id":"e11fa619-feab-4b71-950e-0952bd0a0f35","acronym":"","url":"https://clinicaltrials.gov/study/NCT02332980","created_at":"2021-01-18T11:04:34.890Z","updated_at":"2024-07-02T16:35:24.706Z","phase":"Phase 2","brief_title":"Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT02332980","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • PD-1 • CCND1 • IGH • PD-L2 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • PD-1 • CCND1 • IGH • PD-L2 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • Zydelig (idelalisib)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 02/19/2015","start_date":" 02/19/2015","primary_txt":" Primary completion: 08/10/2021","primary_completion_date":" 08/10/2021","study_txt":" Completion: 01/04/2022","study_completion_date":" 01/04/2022","last_update_posted":"2024-01-03"},{"id":"98a4f025-5ee8-4f15-ae0b-6980e94aaeb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04238637","created_at":"2023-11-19T10:15:04.491Z","updated_at":"2025-02-25T15:09:02.238Z","phase":"Phase 2","brief_title":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","source_id_and_acronym":"NCT04238637","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-18"},{"id":"ded56621-91d5-4fd3-83a0-0e173411e008","acronym":"","url":"https://clinicaltrials.gov/study/NCT05519397","created_at":"2022-08-29T13:03:09.156Z","updated_at":"2024-07-02T16:35:37.582Z","phase":"","brief_title":"Evaluation of the Role of Immune Checkpoints in Response to Breast Cancer Neoadjuvant Therapy","source_id_and_acronym":"NCT05519397","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • PD-L2 • HAVCR2 • IL2RA • CD27 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • PD-L2 • HAVCR2 • IL2RA • CD27 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2023-09-11"},{"id":"7e21b1c1-21f0-4b37-a171-fa51196f862e","acronym":"IMMUNIB","url":"https://clinicaltrials.gov/study/NCT03841201","created_at":"2021-01-18T18:57:47.456Z","updated_at":"2025-02-25T13:35:14.380Z","phase":"Phase 2","brief_title":"Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma","source_id_and_acronym":"NCT03841201 - IMMUNIB","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75","pipe":"","alterations":" ","tags":["CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 05/02/2023","study_completion_date":" 05/02/2023","last_update_posted":"2023-05-12"},{"id":"bf9c7e1e-2dfc-4a8f-afc2-0cca15233b10","acronym":"","url":"https://clinicaltrials.gov/study/NCT05163483","created_at":"2021-12-20T15:53:34.277Z","updated_at":"2024-07-02T16:35:54.064Z","phase":"Phase 2","brief_title":"Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer","source_id_and_acronym":"NCT05163483","lead_sponsor":"Ruihua Xu","biomarkers":" PD-L1 • PD-L2","pipe":"","alterations":" ","tags":["PD-L1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-03-06"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"0f6a5fa5-1b4c-4e95-8ba5-d43403ecfef2","acronym":"NISCAHN","url":"https://clinicaltrials.gov/study/NCT03132038","created_at":"2021-01-18T15:25:54.239Z","updated_at":"2024-07-02T16:36:18.714Z","phase":"Phase 2","brief_title":"Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck","source_id_and_acronym":"NCT03132038 - NISCAHN","lead_sponsor":"UNICANCER","biomarkers":" PD-L1 • PD-L2","pipe":" | ","alterations":" TILs","tags":["PD-L1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 03/24/2017","start_date":" 03/24/2017","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 10/20/2021","study_completion_date":" 10/20/2021","last_update_posted":"2022-01-11"},{"id":"c0bf121c-6f22-4255-bac5-d33472b5919a","acronym":"MITO CERV 3","url":"https://clinicaltrials.gov/study/NCT04238988","created_at":"2021-01-18T20:36:32.057Z","updated_at":"2025-02-25T16:09:53.518Z","phase":"Phase 2","brief_title":"Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer","source_id_and_acronym":"NCT04238988 - MITO CERV 3","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" PD-L1 • PD-1 • IL6 • CTLA4 • PD-L2 • CD4 • ICOS • IL10 • FAS • FOXP3 • TNFSF4","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • IL6 • CTLA4 • PD-L2 • CD4 • ICOS • IL10 • FAS • FOXP3 • TNFSF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-08-27"},{"id":"8b0e1f4c-85b6-4885-83d1-ee944387e8b0","acronym":"PARIS","url":"https://clinicaltrials.gov/study/NCT03245177","created_at":"2021-01-18T16:02:08.350Z","updated_at":"2025-02-25T16:06:41.222Z","phase":"Phase 1","brief_title":"Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03245177 - PARIS","lead_sponsor":"Prof Corinne Faivre-Finn","biomarkers":" PD-L2","pipe":"","alterations":" ","tags":["PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2017","start_date":" 08/01/2017","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2021-07-28"},{"id":"56840cd1-de4a-4f57-9498-f5727132e914","acronym":"","url":"https://clinicaltrials.gov/study/NCT04418219","created_at":"2021-01-18T21:17:41.922Z","updated_at":"2024-07-02T16:36:29.480Z","phase":"Phase 1/2","brief_title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","source_id_and_acronym":"NCT04418219","lead_sponsor":"Thomas Jefferson University","biomarkers":" HER-2 • PD-L1 • ER • PGR • PD-L2 • HLA-B • PRAME • HLA-C","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative • HLA-A*24","tags":["HER-2 • PD-L1 • ER • PGR • PD-L2 • HLA-B • PRAME • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Bria-IMT (SV-BR-1-GM) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2021-06-07"}]